Ipsen acquires Simcere Zaiming’s innovative ADC SIM0613
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The inspection concluded with one minor observation in Form 483
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Akero became a wholly owned subsidiary of Novo Nordisk
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Subscribe To Our Newsletter & Stay Updated